文献速递湿疹皮炎与荨麻疹

肤色深人群湿疹严重度评分:当前最佳实践综述与未来改进需求

Eczema Severity Scoring in Skin of Color: A Review of Current Best Practice and Need for Future Improvement.
PubMed 文献 · J Invest Dermatol · 2025-02-24

该综述聚焦特应性皮炎(AD)在肤色深人群中的严重度评估工具。常用量表初始验证时肤色深人群代表性不足或未报告种族与肤色,已有调整方案如EASI红斑分上调1分但未验证,灰阶替代红斑可改善评分者间信度。患者报告结局不宜直接合并,针对黑人皮肤的PoSCORAD是已验证的特异性工具,生物标志物、光子检测等新方法尚待进一步研究。

要点

  • 常用AD严重度评估工具在肤色深人群中验证不足,需谨慎解读。
  • EASI红斑分上调1分尚未验证,灰阶替代红斑可改善评分者间信度。
  • 不同种族患者报告结局不宜合并,PoSCORAD为黑人皮肤验证工具。

核心结论

  • 常用AD严重度评估工具在肤色深人群中初始验证代表性不足,需开发、调整和验证适合该人群的评估工具。

研究设计与样本

  • 综述,检索并总结肤色深人群中AD常用及新型结局评估工具的相关研究。

主要发现

  • 常用AD结局评估工具的初始验证研究对肤色深人群代表性不足或未报告种族、族裔和肤色。
  • 在肤色深患者中使用EASI时建议将红斑评分上调1分,但尚未验证。
  • 使用灰阶替代红斑成分可改善评分者间信度。
  • 不同族裔或肤色深患者受AD影响方式可能不同,因此不推荐合并患者报告结局测量。
  • 针对黑人皮肤的PoSCORAD是已专门调整并验证的患者报告结局工具。

关键数值与推荐

  • EASI红斑分上调1分尚未验证;灰阶替代红斑可改善评分者间信度;不推荐合并患者报告结局;PoSCORAD为黑人皮肤验证工具。

临床怎么用

  • 临床评估肤色深AD患者时,应意识到常用量表的局限性,可参考灰阶替代红斑或PoSCORAD等调整方案。

局限性

  • EASI红斑分上调1分的建议尚未验证;新型评估方法如生物标志物、光子检测等仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patient- and investigator-reported outcome measures are used in research and clinical practice to assess the severity and impact of atopic dermatitis (AD). Initial validation studies of the most commonly used outcome measures for AD underrepresent patients with skin of color or fail to report race, ethnicity, and skin color altogether. Various adaptations have been proposed. Upgrading the erythema score by 1 when using the Eczema Area and Severity Index in patients with skin of color has been suggested but has not yet been validated. However, the use of a "grey scale" in place of the erythema component has been reported to improve inter-rater reliability. Patients of different ethnicities or with skin of color may be impacted in different ways by AD. The pooling of patient-reported outcome measures is therefore not recommended. The Patient-orientated SCORing for Atopic Dermatitis tool for Black skin is an example of a patient-reported outcome measure specifically adapted and validated for Black skin. Novel methods for assessing AD severity include biomarker assessment using tape strips, photonic testing, and measuring subepidermal low echogenic band thickness. In this article, we review the common and novel AD outcome measures in patients with skin of color to highlight best practices and where further research to develop, adapt, and validate outcome measures will be of benefit to patients with AD with skin of color or from minoritized ethnic groups.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kamp E, Ascott A, George SMC, et al. Eczema Severity Scoring in Skin of Color: A Review of Current Best Practice and Need for Future Improvement. J Invest Dermatol. 2025. PMID: 39998455. doi:10.1016/j.jid.2025.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。